Patient-centered Care for Opioid Use Disorder David R. Gastfriend, - - PowerPoint PPT Presentation

▶
patient centered care for opioid use disorder
SMART_READER_LITE
LIVE PREVIEW

Patient-centered Care for Opioid Use Disorder David R. Gastfriend, - - PowerPoint PPT Presentation

Dec 06, 2022 47 likes •168 views

Patient-centered Care for Opioid Use Disorder David R. Gastfriend, M.D., DFASAM PI: A Simple Large Trial of Patient-Centered Care for Opioid Use Disorders in FQHCs & Specialty Care Settings Senior Research Scientist: Public Health

slide-1
SLIDE 1

Patient-centered Care for Opioid Use Disorder

David R. Gastfriend, M.D., DFASAM

PI: “A Simple Large Trial of Patient-Centered Care for Opioid Use Disorders in FQHCs & Specialty Care Settings” Senior Research Scientist: Public Health Management Corp., Philadelphia PA November 1, 2018

#PCORI2018

slide-2
SLIDE 2

2 • November 28, 2018

David Gastfriend, MD, DFASAM

Disclosures

Rela latio ionship ip Company ny(ies es) Speakers Bureau blank Advisory Committee blank Consultancy BioCorRx, Horizon BCBS of NJ, IBM Watson Review Panel blank Board Membership blank Honorarium blank Ownership Interests Alkermes Inc., Am. Soc. of Addiction Medicine, DynamiCare Health Inc., Intent Solutions Inc.

slide-3
SLIDE 3

3 • November 28, 2018

Objectives

At the conclusion of this activity, participants should be able to

  • Describe evidence-based treatments for Opioid Use Disorder (OUD)
  • Describe current practices for OUD treatment
  • Describe challenges regarding patient access to treatment
slide-4
SLIDE 4

4 • November 28, 2018

Current & Emerging Practice for Opioid Use Disorder

  • Current Practice: Specialty counseling and detox
  • Office-based opioid treatment (OBOT) is rising
  • Abstinence Model is dominant model
  • Motivational Enhancement Therapy growing
  • American Society of Addiction Medicine (ASAM) Criteria
  • Six dimensions of assessment and treatment: Withdrawal, Biomedical, Psychological,

Readiness, Relapse Potential, Environmental

  • Use the least intensive resource(s) known to yield optimal outcomes
  • Personalized Addiction Treatment-to-Health Model (PATH) Study
  • Randomized control trial (N=800)
  • Compares PATH to community standard (specialty addiction programs)
slide-5
SLIDE 5

5 • November 28, 2018

Evidence-based Treatments for Opioid Use Disorder

  • Medication-assisted treatment (MAT)
  • Agonists: Methadone
  • Partial agonists: Buprenorphine SL/XR
  • Antagonists: Naltrexone PO/XR
  • Contingency management (CM)
  • Cognitive behavioral therapy (CBT)
  • Peer support

Environment Agent Host

slide-6
SLIDE 6

6 • November 28, 2018

Challenges & Solutions for Opioid Use Disorder

Challenges

  • 90% do not seek or receive care
  • Limited resources and access
  • Impaired motivation
  • Stigma
  • Highly fragmented system

Proposed Solution: PATH in Federally Qualified Health Centers (FQHCs)

  • Multidimensional assessment
  • Evidence-based treatment: MAT, CBT, CM, peer support and collaborative care

MAT

Primary Care

Behav’l Health

CM

Peer Support

C M

CBT

Psych Care

slide-7
SLIDE 7

7 • November 28, 2018

Patient Need & Patient Choice Issues

Marked Heterogeneity in the Patient Population Due to

  • Opioid type (i.e.: prescription, heroin, or fentanyl)
  • Route of administration
  • Age, chronicity, and level of function
  • Prior treatment experience and phase of recovery
  • Chronic pain or pain orientation
  • Co-occurring disorders
  • Social chaos or disenfranchisement
  • Discontinuation concerns
slide-8
SLIDE 8

8 • November 28, 2018

Patient Need & Patient Choice Issues, continued

  • MAT selection
  • No predictors yet identified for extended-release naltrexone (XR-NTX)

selection (except need for detox)

  • The best basis for methadone vs. buprenorphine vs. XR-NTX treatment

may be patient preference

  • More evidence needed for initiation and termination decisions
  • Psychosocial services
  • Recovery Model vs. Harm Reduction?
  • Scheduled vs. flexible approaches?
  • Best basis may be patient preference
slide-9
SLIDE 9

9 • November 28, 2018

PATH Pilot Study: Six Implementation Findings

  • In medication-assisted treatment,
  • Most buprenorphine-waivered prescribers don’t prescribe
  • XR-NTX induction is limited
  • Group therapy and peer specialists need reimbursement
  • Contingency management faces policy obstacles, but solutions exist
  • Primary care has brief behavioral focus, but needs a longitudinal focus
  • There is a need more for addiction knowledge, resources are welcome
  • Peer-mediated street recruitment can be very successful
slide-10
SLIDE 10

10 • November 28, 2018

Opportunity for Impact

  • U.S. has 1,367 FQHCs
  • Reach more than 10,000 communities
  • Serve more than 25 million people (or

~1 in 12 Americans)

  • If PATH shows similar or better

retention/abstinence to usual care, then dissemination of this successful, feasible model of care could substantially improve access and outcomes in the epidemic

slide-11
SLIDE 11

11 • November 28, 2018

Learn More

  • www.pcori.org
  • info@pcori.org
  • #PCORI2018
  • https/empower.Stanford.edu
slide-12
SLIDE 12

12 • November 28, 2018

Thank You!

David R. Gastfriend, M.D., DFASAM

PI: “A Simple Large Trial of Patient-Centered Care for Opioid Use Disorders in FQHCs & Specialty Care Settings” Senior Research Scientist: Public Health Management Corp., Philadelphia PA November 1, 2018